Description
Niraparib
Each film-coated tablet contains Niraparib tosylate monohydrate159.3mg equivalent to Niraparib … 100mg.
INDICATION
LuciNira is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: • For the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinumbased chemotherapy. • For the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA -mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum -based chemotherapy. Select patients for therapy based on an FDA -approved companiondiagnostic for LuciNira.
DOSAGE AND USE
• First-line maintenance treatment of advanced ovarian cancer: For patients weighing <77 kg (<170 lbs) OR with a platelet count <150,000/mcL, the recommended dosage is 200 mg taken orally once daily. For patients weighing ≥77 kg (170 lbs) AND a platelet count ≥150,000/ mcL, the recommended dosage is 300 mg taken orally once daily. • Maintenance treatment of recurrent germline BRCA -mutated ovarian cancer: The recommended dosage is 300 mg taken orally once daily.
If you miss a dose of LuciNira, take your next dose at your scheduled time. Do not take an extra dose to make up for a missed dose.
STORAGE
In a dry place and store at 20°C to 25°C.
MANUFACTURED AND MARKETED BY
LUCIUS PHARMACEUTICALS(LAO) CO., LTD. No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNINGS
Keep medicine out of reach of Children. Do not administer LuciNira during Pregnancy and Lactation.
Reviews
There are no reviews yet.